Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Pashna N. Munshi"'
Autor:
Kwang Woo Ahn, Peiman Hematti, Mohamed A. Kharfan-Dabaja, Pashna N. Munshi, Mazyar Shadman, Siddhartha Ganguly, Farhad Khimani, Marcelo C. Pasquini, Alex F. Herrera, Jonathon B. Cohen, Mehdi Hamadani, Yue Chen, Jean Yared, Cameron J. Turtle, Patrick M. Reagan, Frederick L. Locke, Craig S. Sauter, Reid W. Merryman, Amer Beitinjaneh, Nausheen Ahmed
Publikováno v:
Blood. 139:1330-1339
The relative efficacy of autologous hematopoietic cell transplant (auto-HCT) vs chimeric antigen receptor T-cell (CAR-T) therapy in patients with diffuse large B-cell lymphoma (DLBCL) who achieve a partial remission (PR) after salvage chemotherapy is
Autor:
Omar Davila, Muzaffar H. Qazilbash, Parameswaran Hari, Nina Shah, Pashna N. Munshi, Shaji Kumar, David H. Vesole, Andrew St. Martin, Anita D'Souza
Publikováno v:
Cancer, vol 127, iss 22
BACKGROUND Consolidative autologous hematopoietic stem cell transplantation (AHCT) is commonly used for patients with multiple myeloma (MM). We studied AHCT use and outcomes in patients with MM ≥75 years old. METHODS Patients with MM ≥75 years ol
Autor:
Miguel Angel Diaz, David Szwajcer, Lynette C.Y. Chee, Claudio G. Brunstein, Mary Eapen, Nina Orfali, David A. Rizzieri, Timothy Prestidge, Ian K. McNiece, Olle Ringdén, Melhem Solh, Pashna N. Munshi, Michael R. Grunwald, Sachiko Seo, Hillard M. Lazarus, Muhammad Bilal Abid, Mei-Jie Zhang, Filippo Milano, Jean A. Yared, Peiman Hematti, Jaap Jan Boelens, Mariam Allbee-Johnson, Marcie L. Riches, Scott D. Solomon, Andrew S. Artz, Jingmei Hsu, Koen van Besien
Publikováno v:
Transplant Cell Ther
The in vivo depletion of recipient and donor T lymphocytes using antithymocyte globulin (ATG; Thymoglobulin) is widely adopted in allogeneic hematopoietic stem cell transplantation (HCT) to reduce the incidence of both graft failure and graft-versus-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bac04ae666f791dd92ad2942b1a5b227
https://europepmc.org/articles/PMC8671234/
https://europepmc.org/articles/PMC8671234/
Autor:
Carmelo Carlo-Stella, Kami J. Maddocks, Sairah Ahmed, Manali Kamdar, Mazyar Shadman, Mahmoud Aljurf, Tycel Phillips, Brad S. Kahl, David J. Inwards, Martin Dreyling, Frederick L. Locke, Mohamed A. Kharfan-Dabaja, Nilanjan Ghosh, Amanda F. Cashen, Michael Wang, Jonathan W. Friedberg, Anna Sureda, Mats Jerkeman, Stephen P. Robinson, Matthew A. Lunning, Timothy S. Fenske, Jonathon B. Cohen, John P. Leonard, Craig S. Sauter, Alex F. Herrera, Pashna N. Munshi, Vaishalee P. Kenkre, Bipin N. Savani, Peter Dreger, Veronika Bachanova, Mehdi Hamadani, Ambuj Kumar, Sonali M. Smith, Brian T. Hill
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
Transplantation and cellular therapy
Universidad de Barcelona
Transplantation and cellular therapy
Autologous (auto-) and allogeneic (allo-) hematopoietic cell transplantation (HCT) are accepted treatment modalities in contemporary treatment algorithms for mantle cell lymphoma (MCL). Chimeric antigen receptor (CAR) T cell therapy recently received
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7add1b94fdc73da4cadeabe5841d900
http://hdl.handle.net/2445/180086
http://hdl.handle.net/2445/180086
Autor:
Jacqueline W. Mays, Sandra A. Mitchell, Filip Pirsl, Lindsay M. Morton, Claire L. Ruben, Galen O. Joe, Leora E. Comis, Jeannette Nashed, Seth M. Steinberg, Steven Z. Pavletic, Pashna N. Munshi, Alen Ostojić, Noa G. Holtzman, Dana A. Schaar, Edward W. Cowen
Publikováno v:
Transplant Cell Ther
Subsequent cancer (SC) is a significant cause of morbidity and mortality in long-term survivors after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Chronic graft-versus-host disease (cGVHD) and treatment-related immunosuppression ha
Autor:
Kwang Woo Ahn, Mohamed A. Kharfan-Dabaja, Nirav N. Shah, Farhad Khimani, Praveen Ramakrishnan Geethakumari, Sairah Ahmed, Yue Chen, Sachiko Seo, Nilanjan Ghosh, Narendranath Epperla, Mehdi Hamadani, Sanghee Hong, Amer Beitinjaneh, Pashna N. Munshi, Tim Prestidge, Leona Holmberg, Victor A. Chow, Michael Scordo, Yago Nieto, Natalie S Grover, Umar Farooq, Nada Hamad, Reem Karmali, Gerhard C. Hildebrandt, Andrew R. Rezvani, Jean A. Yared, Antonio Jimenez-Jimenez, Maxwell M. Krem, Bhagirathbhai Dholaria, Evgeny Klyuchnikov, Craig S. Sauter, David J. Inwards, Peter A. Riedell, Trent P Wang, Farrukh T. Awan, Alex F. Herrera, Andy I. Chen, Melhem Solh, Vaishalee P. Kenkre
Publikováno v:
JAMA Oncol
IMPORTANCE: Primary central nervous system lymphoma (PCNSL) requires induction and consolidation to achieve potential cure. High-dose therapy and autologous hematopoietic cell transplant (AHCT) is an accepted and effective consolidation strategy for
Autor:
Ambuj Kumar, Anna Sureda, Jonathon B. Cohen, Veronika Bachanova, Kami J. Maddocks, Jonathan W. Friedberg, Mehdi Hamadani, Sonali M. Smith, Sairah Ahmed, John P. Leonard, Brad S. Kahl, Craig S. Sauter, Timothy S. Fenske, Frederick L. Locke, Carmello Carlo-Stella, Brian T. Hill, Mohamed A. Kharfan-Dabaja, Amanda F. Cashen, Mazyar Shadman, Michael Wang, Mahmoud Aljurf, Tycel Phillips, Pashna N. Munshi, Alex F. Herrera, Bipin N. Savani, Nilanjan Ghosh, David J. Inwards, Mats Jerkeman, Martin Dreyling, Vaishalee P. Kenkre, Matthew A. Lunning, Peter Dreger, Stephen P. Robinson, Manali Kamdar
Publikováno v:
Bone marrow transplantation. 56(12)
Autologous (auto-) or allogeneic (allo-) hematopoietic cell transplantation (HCT) are accepted treatment modalities for mantle cell lymphoma (MCL). Recently, chimeric antigen receptor (CAR) T-cell therapy received approval for MCL; however, its exact
Autor:
Alan P Skarbnik, Paul Fields, Pashna N. Munshi, Michele L. Donato, Scott D. Rowley, Joshua Zenreich, Tatyana Feldman, Andrew L. Pecora, David H. Vesole, Lori A. Leslie, Dante B. Descalzi-Montoya, Andre Goy, Noa Biran, Themba Nyirenda, Rena Feinman, Robert Korngold
Publikováno v:
Transplantation and cellular therapy. 27(5)
Autologous hematopoietic stem cell transplantation (ASCT) is a standard-of-care treatment for many hematologic malignancies. Progression of disease after ASCT is the primary cause of treatment failure. In this Phase Ib trial, we studied the safety an
Autor:
Gunjan L. Shah, Sherif M. Badawy, Nosha Farhadfar, Jason Tay, Mohamed A. Kharfan-Dabaja, Shaji Kumar, Minoo Battiwalla, Sachiko Seo, Rebecca L. Olin, Kenneth R. Meehan, Parameswaran Hari, Richard F. Olsson, Pashna N. Munshi, Muzaffar H. Qazilbash, Maxwell M. Krem, Hemant S. Murthy, Artur Jurczyszyn, Anita D'Souza, Jeffrey Schriber, Saurabh Chhabra, Siddhartha Ganguly, Vaibhav Agrawal, Omar Davila, Melhem Solh, Taiga Nishihori, Hillard M. Lazarus, Ehsan Malek, Nina Shah, Andrew St. Martin, Jan Maciej Zaucha, Shahrukh K. Hashmi, David H. Vesole, Edward A. Copelan
Publikováno v:
Cancer
BACKGROUND Upfront autologous hematopoietic stem cell transplantation (AHCT) remains an important therapy in the management of patients with multiple myeloma (MM), a disease of older adults. METHODS The authors investigated the outcomes of AHCT in pa
Autor:
Reem Karmali, Ayman Saad, Kwang Woo Ahn, Melhem Solh, Ravi Vij, Mohamed A. Kharfan-Dabaja, Nirav N. Shah, Timothy S. Fenske, William A. Wood, Mehdi Hamadani, Amir Steinberg, Carlos Litovich, Pashna N. Munshi, Alexsandr Lazaryan, Usama Gergis, Siddhartha Ganguly, David J. Inwards, Sonali M. Smith, Lazaros J. Lekakis, Anna Sureda, Farrukh T. Awan, Sunita Nathan
Publikováno v:
Blood Cancer Journal, Vol 9, Iss 12, Pp 1-10 (2019)
Blood Cancer Journal
Blood Cancer Journal
Allogeneic hematopoietic cell transplantation (allo-HCT) is a curative therapy for relapsed/refractory and high-risk non-Hodgkin lymphoma (NHL). However, no large studies have evaluated allo-HCT utilization in elderly NHL patients (≥65 years). Usin